Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms

Myelodysplastic syndromes

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Lancet Haematol

Porta MGD, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U

doi: 10.1016/S2352-3026(24)00203-5

Myelodysplastic syndromes

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Lancet Haematol

Garelius HKG, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, Mittelmann M, Stauder R, Čermák J, Sanz G, Langemeijer S, Malcovati L, Germing U, Sanhes L, d'Aveni M, Culligan D, Kotsianidis I, Koinig KA, van Marrewijk C, Crouch S, deWitte T, Smith A, Hellström-Lindberg E

doi: 10.1016/S2352-3026(24)00350-8

ASCO 2024

Gynecologic Cancer

Estrogen-only hormone therapy may increase ovarian cancer risk, while estrogen-progestin combination may lower the risk of endometrial cancer

Myelodysplastic syndromes

Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?

Blood

Scheid C, Eikema DJ, Van Gelder M, Salmenniemi U, Maertens J MD, Passweg JR, Blaise D, Byrne JL, Kroeger N, Sockel K, Chevallier P, Bourhis JH, Cornelissen JJ, Sengeloev H, Finke J, Snowden JA, Gedde-Dahl T, Cornillon J, Schanz U, Patel A, Koster L, de Wreede LC, Hayden PJ, Raj K, Drozd-Sokolowska J, Gurnari C, Onida F, McLornan DP, Robin M, Yakoub-Agha I

doi: 10.1182/blood.2023022273

Myelodysplastic syndromes

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Lancet Haematol

Díez-Campelo M, López-Cadenas F, Xicoy B, Lumbreras E, González T, Del Rey González M, Sánchez-García J, Coll Jordà R, Slama B, Hernández-Rivas JÁ, Thepot S, Bernal T, Guerci-Bresler A, Bargay J, Amigo ML, Preudhomme C, Fenwarth L, Platzbecker U, Götze KS, Arar A, Toribio S, Del Cañizo C, Hernández-Rivas JM, Fenaux P

doi: 10.1016/S2352-3026(24)00142-X

Central Nervous System Tumors

Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study

J Clin Oncol

Westerveld ASR, Tytgat GAM, van Santen HM, van Noesel MM, Loonen J, de Vries ACH, Louwerens M, Koopman MMW, van der Heiden-van der Loo M, Janssens GO, de Krijger RR, Ronckers CM, van der Pal HJH, Kremer LCM, Teepen JC

doi: 10.1200/JCO.23.01430

Leukemia

Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes

Br J Haematol

Tinajero J, Xu S, Ngo D, Li S, Palmer J, Nguyen T, Stein A, Koller P, Agrawal V, Pourhassan H, Murphy L, Forman S, Douer D, Marcucci G, Pullarkat V, Aldoss I

doi: 10.1111/bjh.19880

Leukemia

Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases

Am J Hematol

Fathima S, Abdelmagid M, Alsugair A, Begna KH, Al-Kali A, Mangaonkar AA, Pardanani AD, Patnaik MM, Zepeda Mendoza CJ, He R, Reichard KK, Badar T, Foran JM, Palmer J, Loscocco GG, Guglielmelli P, Vannucchi AM, Orazi A, Arber DA, Hiwase D, Shah MV, Gangat N, Tefferi A

doi: 10.1002/ajh.27670

Lymphoma

Related content

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Estrogen-only hormone therapy may increase ovarian cancer risk, while estrogen-progestin combination may lower the risk of endometrial cancer

Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study

Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes

Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL